Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,204 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.60
-10.01%
3.47
Revenue and Profits:
Net Sales:
47 Million
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-29.7%
0%
-29.7%
6 Months
-31.41%
0%
-31.41%
1 Year
16.43%
0%
16.43%
2 Years
72.03%
0%
72.03%
3 Years
116.38%
0%
116.38%
4 Years
25.73%
0%
25.73%
5 Years
0.08%
0%
0.08%
OssDsign AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
50.08%
EBIT Growth (5y)
10.88%
EBIT to Interest (avg)
-30.71
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.38
Sales to Capital Employed (avg)
0.53
Tax Ratio
1.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.25
EV to EBIT
-38.46
EV to EBITDA
-38.46
EV to Capital Employed
9.46
EV to Sales
7.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-24.60%
ROE (Latest)
-11.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
46.50
29.70
56.57%
Operating Profit (PBDIT) excl Other Income
-7.00
-14.50
51.72%
Interest
0.90
0.10
800.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.30
-15.70
47.13%
Operating Profit Margin (Excl OI)
-150.40%
-486.10%
33.57%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 56.57% vs 23.75% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 47.13% vs 22.66% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
133.90
112.20
19.34%
Operating Profit (PBDIT) excl Other Income
-44.00
-80.70
45.48%
Interest
0.10
0.40
-75.00%
Exceptional Items
-4.70
-42.70
88.99%
Consolidate Net Profit
-49.70
-130.50
61.92%
Operating Profit Margin (Excl OI)
-355.80%
-793.00%
43.72%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 19.34% vs 96.84% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 61.92% vs -31.29% in Dec 2023
About OssDsign AB 
OssDsign AB
Pharmaceuticals & Biotechnology
OssDsign AB, formerly known as Oss-Q AB is a Sweden-based orthopedic medical device company. It aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The Company uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The Company's customers include neurosurgeons, craniofacial and maxillofacial surgeons.
Company Coordinates 
Company Details
Uppsala Business Park, Rapsgatan 7 , UPPSALA None : 754 50
Registrar Details






